# Jupiter Neurosciences Inc. (JUNS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $8M  
**Price:** $0.23 (+1.02%)

> Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and related central nervous system disorders. Based in Jupiter, Florida and founded in 2015, the company is built around a proprietary resveratrol-based drug platform designed to deliver this compound in a more effective and bioavailable oral form. Its lead product candidate, JOTROL, targets a broad range of conditions where neuroinflammation is a key component, including various neurodegenerative and rare diseases. Jupiter Neurosciences also integrates its platform into consumer-oriented longevity and wellness formulations under the Nugevia brand, addressing areas such as mitochondrial support, cognitive health, and skin vitality. Operating within the healthcare and biotechnology sectors, the company primarily serves unmet medical needs in CNS and rare disease markets, positioning its resveratrol platform at the intersection of clinical therapeutics and scientifically grounded wellness solutions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $21,796 | $17,565 | -$9M | -$9M | — |
| 2024 | — | — | -$3M | -$2M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $6M | $7M | -$2M | — | — |
| 2024 | $6M | $2M | $4M | — | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$5M | — | — |
| 2024 | -$4M | — | — |
| 2023 | -$480,953 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/JUNS)